Eli Lilly and Company (LLY) — closed signal from March 16, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 14, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$980.00 – $1,005.00Entry zone — fair-value band
$996.67Published — price the day we called it
$1,126.23Target — the price the thesis aimed for
$1,182.73Peak — highest point inside the window, not a realized return
$1,133.00Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 73 days.
Peak price
$1,182.73
peak on June 8, 2026 — not a realized returnPeak gain
+18.7%
peak, from the publication priceWindow close
$1,133.00
end-of-window price, context onlyDays to target
73
Window
March 16, 2026 – June 14, 2026
The thesis — published March 16, 2026
Predicted growth
+13%
over the measurement windowTarget price
$1,126.23
the price the thesis aimed forEntry zone
$980.00 – $1,005.00
the fair-value band we waited forPrice at publication
$996.67
published March 16, 2026Confidence
84%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly is being recommended because it combines steady growth with more stable earnings than many fast-moving stocks. Recent good trial results for children and continued strong demand for tirzepatide make the company's sales story stronger, and the recent price pullback gives a cleaner chance to buy, though drug-pricing headlines remain a risk.
Primary drivers
- Strong ongoing demand for tirzepatide supports sales growth
- Positive pediatric trial boosts confidence in the drug pipeline
- Healthcare business is comparatively steady in volatile markets
- Buying on a pullback improves potential reward versus risk
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.